Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP)

Report highlights how COVID hindered the fight against antimicrobial resistance   The Department of Health and Human Services (HHS) has highlighted how the COVID-19 pandemic disrupted U.S. efforts to combat antimicrobial resistance (AMR), resulting in a 15% rise in drug-resistant hospital-acquired infections and AMR-related deaths in its first year.   The report emphasizes that preparedness for future public health emergencies must include robust AMR management strategies, timely access to diagnostics and data, and institutional support to sustain stewardship practices, as AMR rates remain elevated post-pandemic. Key lessons underscore the importance of investing in stewardship programs as a cornerstone of pandemic preparedness to mitigate similar challenges in the future.   https://lnkd.in/dSzBsfVv   Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) remains dedicated to addressing antimicrobial resistance by developing a new class of antibiotics for difficult-to-treat bacterial infections. As the fight against AMR continues, sustainable solutions are more critical than ever.   #AntibioticResistance #AMR #GlobalHealth #Nasdaq #AcurxPharma #InnovationInHealthcare

Fighting A Global Threat: How the Chamber Is Combating Antimicrobial Resistance   Coordinated global action, with strong leadership from Capitol Hill, is critical to combating the threat of antimicrobial resistance (AMR).   https://lnkd.in/deqJ9X86   Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) remains dedicated to addressing antimicrobial resistance by developing a new class of antibiotics for difficult-to-treat bacterial infections. As the fight against AMR continues, sustainable solutions are more critical than ever.   #AntibioticResistance #AMR #GlobalHealth #Nasdaq #AcurxPharma #InnovationInHealthcare

#AntibioticResistance #AMR #GlobalHealth #Nasdaq #AcurxPharma #InnovationInHealthcare Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP)

Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) Receives Positive Regulatory Guidance from #EMA for #Ibezapolstat Phase 3 Program for #C. Difficile Infection (#CDI)   • Acurx has now received positive written responses from the EMA (European Medicines Agency) under its #Scientific Advice Procedure that the #clinical, #non-clinical and #CMC (Chemistry Manufacturing and Controls) information package submitted supports advancement of the ibezapolstat Phase 3 program • The responses also included guidance on ibezapolstat's regulatory pathway for a Marketing Authorization Application for ibezapolstat in CDI • With mutually consistent feedback from both EMA and FDA, Acurx is well positioned to commence our international Phase 3 registration program • Acurx is also preparing to request regulatory guidance to initiate clinical trials in Japan, Canada and the United Kingdom • Ibezapolstat has previously been granted #FDA QIDP and Fast-Track Designation from FDA and Acurx has received SME (Small and Medium-sized Enterprise) designation by the EMA to benefit from fee incentives and other support from the EMA for EU Marketing Authorization   https://lnkd.in/ekKCFWdT #nasdaq #acxp #antibiotics #acurx

Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules   Acurx Pharmaceuticals, Inc. (#NASDAQ: #ACXP), a late-stage #biopharmaceutical company developing a new class of #antibiotics for difficult-to-treat #bacterial #infections, announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 2,463,058 shares of its common stock at a purchase price of $1.015 per share in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered warrants to purchase up to 2,463,058 shares of common stock. The warrants will have an exercise price of $0.90 per share, will be exercisable upon issuance and expire five years following the date of issuance. The closing of the offering is expected to occur on or about January 7, 2025, subject to the satisfaction of customary closing conditions.   https://lnkd.in/eejXvv3M #nasdaq #acxp #antibiotics #acurx

Estimates suggest that by 2050, death rates from AMRs will have doubled, with figures indicating almost 40 million people will lose their lives to superbugs over the next 25 years, with elderly people especially at risk.   https://lnkd.in/es7HvD8j   Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) remains dedicated to addressing this crisis by developing a new class of antibiotics for difficult-to-treat bacterial infections. As the fight against AMR continues, sustainable solutions are more critical than ever.   #AntibioticResistance #AMR #GlobalHealth #Nasdaq #AcurxPharma #InnovationInHealthcare

The Looming Crisis Of Antibiotic Resistance   Imagine a world where a simple infection could be deadly. New research suggests this scenario isn’t science fiction – it’s a real possibility that could arrive sooner than we think. Northern Arizona University scientists warn that the growing resistance of bacteria to antibiotics may lead to a sudden, dramatic spike in infection-related deaths.   https://lnkd.in/ezE-yieT   Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) remains dedicated to addressing this crisis by developing a new class of antibiotics for difficult-to-treat bacterial infections. As the fight against AMR continues, sustainable solutions are more critical than ever.   #AntibioticResistance #AMR #GlobalHealth #Nasdaq #AcurxPharma #InnovationInHealthcare

As we welcome the New Year, all of us at Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) want to take a moment to reflect on the progress we’ve made together. In 2024, we achieved significant milestones, including advancing #ibezapolstat toward Phase 3 clinical trials and securing critical patent protections that strengthen our mission to fight serious bacterial infections. These accomplishments are not just steps forward for our company—they represent hope for better patient outcomes and healthier futures.    Thank you to our team, partners, and supporters who make this work possible.    Wishing you all a happy, healthy, and successful New Year!

Merry Christmas from Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP)!   Wishing you a joyful holiday season filled with health, happiness, and exciting advancements for the year ahead.

Ibezapolstat: Transforming the Treatment of C. difficile Infection (#CDI)   #C. difficile infection impacts nearly 500,000 people in the U.S. annually, with many facing severe complications and recurrence.    Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP)' lead candidate, #Ibezapolstat, offers a novel approach to addressing this critical health issue.   With its innovative mechanism as a DNA polymerase IIIC inhibitor, Ibezapolstat targets CDI effectively while preserving gut microbiome health.    Backed by promising clinical trial results and FDA designations like QIDP and Fast Track status, it is advancing toward Phase 3 trials with the potential to reshape CDI treatment.   Learn more at www.acurxpharma.com